Rilling G, Tettenborn B
Klinik für Neurologie, Kantonsspital St. Gallen.
Praxis (Bern 1994). 2001 Aug 16;90(33):1350-4.
The treatment of myasthenia gravis is a difficult entity. We especially discuss the immunosuppressive treatment with regard to the literature. In patients with thymoma all authors agree in thymectomy. In generalized myasthenia, even without thymoma, thymectomy should be performed in "younger" patients. In "elderly" patients thymectomy as treatment of choice is controversial. The basis of immunsuppressive therapy are corticosteroids, additionally azathioprine can be given considering the delay in response and the major side effects. As today, cyclophosphamide and cyclosporine A are too toxic for routine use, except third choice in therapy resistant patients as ultima ratio. The procedure of choice in myasthenic crisis is plasma exchange if the patient tolerates it. Alternatively intravenous immunoglobulin should be given. In pure ocular myasthenia treatment is controversial in the literature. In the last few years there is a tendency to treat this form early like generalized myasthenia, especially in young patients, to prevent generalization.
重症肌无力的治疗是一个复杂的问题。我们特别根据文献讨论了免疫抑制治疗。对于胸腺瘤患者,所有作者都同意进行胸腺切除术。在全身型重症肌无力患者中,即使没有胸腺瘤,“年轻”患者也应进行胸腺切除术。对于“老年”患者,胸腺切除术作为首选治疗方法存在争议。免疫抑制治疗的基础是皮质类固醇,考虑到起效延迟和主要副作用,还可加用硫唑嘌呤。如今,环磷酰胺和环孢素A毒性太大,不适合常规使用,除非作为治疗抵抗患者的最后手段的第三选择。如果患者能够耐受,在重症肌无力危象中首选的治疗方法是血浆置换。另外,应给予静脉注射免疫球蛋白。在单纯眼肌型重症肌无力的治疗方面,文献中存在争议。在过去几年中,有一种趋势是像治疗全身型重症肌无力一样早期治疗这种类型,尤其是在年轻患者中,以防止病情发展。